Hematology CME & Oncology CME

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

CME
Electro-Gene Therapy with IL-12 Plasmid in Metastatic Melanoma
May 8, 2013
This activity will discuss the safety, efficacy, and side effects of IL-12, as shown in Phase I and Phase II studies… More »
This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 0.25

CME
Debate: “Interferon Sensitivity”: Adjuvant IFN Should Be Used Only in Patients with Ulceration and/or Microscopic Nodal Disease
May 2, 2013
This activity will feature two experts debating the efficacy of high-dose, intermediate-dose and low-dose interferon in melanoma patients in various disease stages and with certain characteristics,… More »
This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 0.5

CME
Does Biochemotherapy Have a Role in Adjuvant Therapy?
May 2, 2013
This activity will discuss the role of biochemotherapy in adjuvant therapy when treating high-risk melanoma patients… More »
This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 0.25

CME
Current Status of Injectable Therapy
April 9, 2013
This activity will review intralesional therapies, both those available and in development; discuss response rates to intralesional therapies; discuss adverse reactions to intralesional therapies;… More »
This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 0.5

PROMOTIONAL
Treatment Considerations in Metastatic Melanoma
November 29, 2012
Treating metastatic melanoma has been a significant challenge with a 1-year mortality rate of 75% and median survival time of 6 months. There are few treatment options for patients and little… More »
This promotional spotlight is presented by Bristol-Myers Squibb.

CME
HOT Melanoma 2012: Metastatic Melanoma — Targeting the Genome and the Blood Vessels
November 28, 2012
Melanoma, the deadliest form of skin cancer, can be curable if caught early. Treatment options are limited for patients with advanced disease, and prognosis is poor. Earlier detection, appropriate… More »
The content contained in this activity was developed from the live activity that was supported, in part, by educational grants from Bristol-Myers Squibb, Genentech, Merck & Co., Inc., Prometheus Laboratories, Inc., and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 2

CME
HOT Melanoma 2012: Metastatic Melanoma - Immunotherapy
November 20, 2012
Melanoma, the deadliest form of skin cancer, can be curable if caught early. Treatment options are limited for patients with advanced disease, and prognosis is poor. Earlier detection, appropriate… More »
The content contained in this activity was developed from the live activity that was supported, in part, by educational grants from Bristol-Myers Squibb, Genentech, Merck & Co., Inc., Prometheus Laboratories, Inc., and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 2

CME
HOT Melanoma 2012: Surgery and Adjuvant Therapy
November 19, 2012
Melanoma, the deadliest form of skin cancer, can be curable if caught early. Treatment options are limited for patients with advanced disease, and prognosis is poor. Earlier detection, appropriate… More »
The content contained in this activity was developed from the live activity that was supported, in part, by educational grants from Bristol-Myers Squibb, Genentech, Merck & Co., Inc., Prometheus Laboratories, Inc., and Provectus Pharmaceuticals, Inc.
Credit Type(s): CME | Credit: 1.5

CMECNE
Practical Approaches to Metastatic Melanoma in the Molecular Era
November 10, 2012
Clinical experts review the most significant issues related to the treatment of patients with metastatic melanoma. This discussion includes new therapies approved by the FDA, the use of immunotherapy… More »
This activity is supported by educational grants from Bristol-Myers Squibb and Genentech.
Credit Type(s): CME / CNE | Credit: 1.25

CMECNEVIDEO
Practical Approaches to Metastatic Melanoma in the Molecular Era: Case Challenges
September 25, 2012
Emerging treatment options for metastatic melanoma have the potential to significantly improve patient outcomes. Knowledge of how to effectively implement these therapies into practice is essential… More »
This activity is supported by educational grants from Bristol-Myers Squibb and Genentech.
Credit Type(s): CME / CNE | Credit: 0.5

Hematology/Oncology